These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35357770)

  • 1. Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany.
    Tergast TL; Blach S; Tacke F; Berg T; Cornberg M; Kautz A; Manns M; Razavi H; Sarrazin C; Serfert Y; van Thiel I; Zeuzem S; Wedemeyer H
    J Viral Hepat; 2022 Jul; 29(7):536-542. PubMed ID: 35357770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic.
    Schorr O; Blach S; Thurnheer C; Ruis C; Dufour JF
    PLoS One; 2022; 17(8):e0272518. PubMed ID: 35960770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
    Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
    Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Securing wider EU commitment to the elimination of hepatitis C virus.
    Wedemeyer H; Tergast TL; Lazarus JV; Razavi H; Bakoyannis K; Baptista-Leite R; Bartoli M; Bruggmann P; Buşoi CS; Buti M; Carballo M; Castera L; Colombo M; Coutinho RS; Dadon Y; Esmat G; Esteban R; Farran JC; Gillyon-Powell M; Goldberg D; Hutchinson S; Janssen HLA; Kalamitsis G; Kondili LA; Lambert JS; Marinho RT; Maticic M; Patricello A; Peck-Radosavljevic M; Pol S; Poljak M; Pop C; Sokol T; Sypsa V; Tözün N; Younossi Z; Aghemo A; Papatheodoridis GV; Hatzakis A
    Liver Int; 2023 Feb; 43(2):276-291. PubMed ID: 36196744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishing a framework towards monitoring HCV microelimination among men who have sex with men living with HIV in Germany: A modeling analysis.
    Marquez LK; Ingiliz P; Boesecke C; Krznaric I; Schewe K; Lutz T; Mauss S; Christensen S; Rockstroh JK; Jain S; He F; Wertheim JO; Martin NK
    PLoS One; 2022; 17(5):e0267853. PubMed ID: 35551326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID-19.
    Blach S; Blomé M; Duberg AS; Jerkeman A; Kåberg M; Klasa PE; Lagging M; Razavi-Shearer D; Razavi H; Aleman S
    Liver Int; 2021 Sep; 41(9):2024-2031. PubMed ID: 34051065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress.
    Blach S; Brown KA; Brown RS; Gholam PM; Terrault NA; Estes C; Razavi HA
    J Infect Public Health; 2023 Jan; 16(1):64-70. PubMed ID: 36473359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications.
    Kwon JA; Dore GJ; Hajarizadeh B; Alavi M; Valerio H; Grebely J; Guy R; Gray RT
    PLoS One; 2021; 16(9):e0257369. PubMed ID: 34529711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
    Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
    World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.
    Polaris Observatory HCV Collaborators
    Lancet Gastroenterol Hepatol; 2022 May; 7(5):396-415. PubMed ID: 35180382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W; Razavi H; Estes C; Thompson AJ; Zekry A; Roberts SK; Dore GJ
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A micro-elimination approach to addressing hepatitis C in Turkey.
    Idilman R; Razavi H; Robbins-Scott S; Akarca US; Örmeci N; Kaymakoglu S; Aygen B; Tozun N; Güner R; Bodur H; Lazarus JV
    BMC Health Serv Res; 2020 Mar; 20(1):249. PubMed ID: 32209103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forecasting the long-term impact of COVID-19 on hepatitis C elimination plans in Italy: A mathematical modelling approach.
    Kondili LA; Andreoni M; Aghemo A; Mastroianni CM; Merolla R; Gallinaro V; D'Offizi G; Craxì A
    Liver Int; 2023 Dec; 43(12):2615-2624. PubMed ID: 37735959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis.
    Tada T; Toyoda H; Kumada T; Kurisu A; Sugiyama A; Akita T; Ohisa M; Aikata H; Miki D; Chayama K; Tanaka J
    J Viral Hepat; 2021 Mar; 28(3):538-547. PubMed ID: 33215790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of COVID-19 pandemic on the 2020 hepatitis C cascade of care in the Republic of Georgia.
    Gamkrelidze A; Handanagic S; Shadaker S; Turdziladze A; Tsereteli M; Getia V; Aslanikashvili A; Surguladze S; Gvinjilia L; Kuchuloria T; Tskhomelidze I; Armstrong PA
    Public Health; 2022 Apr; 205():182-186. PubMed ID: 35305459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
    Fraňková S; Urbánek P; Husa P; Němeček V; Razavi H; Razavi-Shearer D; Chlíbek R; Šperl J
    Cent Eur J Public Health; 2019 Jun; 27(2):93-98. PubMed ID: 31241282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease burden of hepatitis C in the Austrian state of Tyrol - Epidemiological data and model analysis to achieve elimination by 2030.
    Schaefer B; Viveiros A; Al-Zoairy R; Blach S; Brandon S; Razavi H; Dorn L; Finkenstedt A; Effenberger M; Graziadei I; Sarcletti M; Tilg H; Zoller H
    PLoS One; 2018; 13(7):e0200750. PubMed ID: 30001427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.